First-in-Class Products:Non-Small Cell Lung Cancer Market

1
Frontier Pharma Non-Small Cell Lung Cancer
Market
2
Summary
Large Degree of Innovation in NSCLC Pipeline The
NSCLC pipeline currently has 389 products in
active development across all stages, but a stark
contrast between the mechanisms of action
employed in the current market and the pipeline
is evident. Where the market comprises primarily
ineffective chemotherapies that target tubulin or
DNA replication, the pipeline shows an incredibly
diverse range of therapies targeting multiple
signaling pathways and molecules integral to
cancer development. This diversity is partially
due to the presence of 122 first-in-class
products, which accounts for 38 of the overall
pipeline therapies that disclosed their target.
In an industry, market and development landscape
that favors first-in-class over
non-first-in-class development in many ways, such
as through faster approval or greater revenue,
this finding has strategic implications for a
wide array of market participants, both large and
small. Despite a high attrition rate in NSCLC,
first-in-class therapies that reach the market
have the potential to transform and improve the
NSCLC treatment landscape. For Further Details
http//www.bigmarketresearch.com/frontier-pharma-n
on-small-cell-lung-cancer-identifying-and-commerci
alizing-first-in-class-innovation-market
3
Report Description

• Alignment of First-in-Class Molecular Target with
  Disease Causation
• The method of characterizing NSCLC tumors is
  currently shifting from the traditional
  histology-based characterization to a more
  specific molecule-based method of
  characterization. This has resulted in the
  identification of key oncogenic mutations in
  NSCLC and has coincided with the rise of targeted
  pipeline therapies, which are designed to target
  proteins in signaling pathways that are
  frequently mutated, amplified or overexpressed in
  NSCLC. Aligning the molecular target with
  disease-causing signaling pathways and frequently
  mutated pathways therapies can benefit from
  reduced systemic cytotoxic effects while still
  inhibiting tumor-promoting signaling. Therefore,
  targeted therapies often display superior safety
  and efficacy to chemotherapies.
• GBI Researchs proprietary analysis showed
  substantial variation in how well NSCLC
  first-in-class targets align to frequent gene
  mutations. Further in-depth analysis identified
  the most promising first-in-class targets based
  on various scientific and clinical parameters.
  Examining scientific and clinical data of
  promising first-in-class targets showed that
  first-in-class status is not, in its own right,
  enough for a successful product however, the
  first-in-class products substantiated by
  scientific and clinical evidence will be exciting
  future prospects with the potential to transform
  the NSCLC market.

4
Key Segment

• First-in-Class Products in Licensing and
  Co-development Deals
• The NSCLC deals landscape appears relatively
  quiet for such a large indication. However,
  analysis showed that of the therapies with
  disclosed deal values there is significant range
  in the value of NSCLC deals. Concerning
  first-in-class specifically, only five licensing
  or co-development deals have been made since
  2006. Despite the low sample size, it is clear
  that the first-in-class NSCLC products offer an
  attractive investment prospect as they command
  much higher deal values and, on average, deals
  occur earlier in development compared to
  non-first-in-class counterparts. Both trends were
  substantiated by industry-wide data that showed
  that, particularly in Phase I, first-in-class
  products would attract larger mean and median
  total deal values. The data highlight that the
  first-in-class deals landscape is different and
  indicates a greater chance of becoming much more
  lucrative than the deals landscape for
  addition-to-class or advance-in-class therapies.
• A total of 117 first-in-class products that are
  currently in development have not yet been
  entered into a licensing or co-development deal.
  In a transforming market that will favor
  innovative, targeted therapies with a strong
  clinical record, there are numerous opportunities
  for strategic alliances to bolster a
  first-in-class portfolio or fund clinical
  development. Although not all are aligned to
  disease-causing signaling pathways, many are
  supported by robust scientific and clinical data,
  making them attractive prospects as both
  therapeutics and investment opportunities.

5
Scope

• The report analyzes innovation in NSCLC in the
  context of the overall pipeline and current
  market landscape. It also analyzes the deals
  landscape surrounding first-in-class products and
  pinpoints in-licensing opportunities. The report
  includes
• A brief introduction to NSCLC, including
  symptoms, pathophysiology, and an overview of
  pharmacotherapy and treatment algorithms
• Extensive categorization of histological and
  molecular features of NSCLC tumors
• Coverage of the changing molecular target
  landscape and particular points of innovation in
  the pipeline
• A comprehensive review of the pipeline for
  first-in-class therapies, analyzed by stage of
  development, molecule type and molecular target
• Identification and assessment of first-in-class
  molecular targets with a particular focus on
  early-stage programs of which clinical utility
  has yet to be evaluated, as well as literature
  reviews of novel molecular targets
• An assessment of the licensing and co-development
  deal landscape for NSCLC therapies and
  benchmarking of deals comparing first-in-class
  and non-first-in-class-products
• Read The Complete Report On http//www.bigmarket
  research.com/frontier-pharma-non-small-cell-lung-c
  ancer-identifying-and-commercializing-first-in-cla
  ss-innovation-market

6
Reasons to buy

• The report will enable business development and
  enable marketing executives to strategize their
  product launches by allowing them to
• Understand the focal shifts in molecular targets
  in the NSCLC pipeline
• Understand the distribution of pipeline programs
  by phase of development, molecule type and
  molecular target
• Access a scientific and clinical analysis of
  first-in-class developmental programs for NSCLC,
  benchmarked against non-first-in-class targets
• Assess the valuations of licensed and
  co-developed NSCLC treatments
• Access a list of the first-in-class therapies
  potentially open to deal-making opportunities
• To Get More Details Enquire _at_ http//www.bigmarket
  research.com/report-enquiry/159536

7
Content

• Table of Contents
• Executive Summary
• Clinical and Commercial Landscape
• Assessment of Pipeline Product Innovation
• Deals and Strategic Consolidations
• Appendix
• Read The Complete TOC _at_ http//www.bigmarketresear
  ch.com/frontier-pharma-non-small-cell-lung-cancer-
  identifying-and-commercializing-first-in-class-inn
  ovation-market

8
Contact Us
Deep Joshi 5933 NE Win Sivers Drive, 205,
Portland, OR 97220 United States Direct 1
[phone] Toll Free 1 [phone] Fax
1 [phone] Email help_at_bigmarketresearch
.com Web http//www.bigmarketresearch.com